World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
29415
World Ranking
18280
National Ranking
1661

Overview

Tessa L. Holyoake was affiliated with the University of Glasgow in the United Kingdom. Their research primarily focused on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong emphasis on subfields such as Hematology, Molecular Biology, Genetics, Oncology, and Pathology and Forensic Medicine.

The scientist's body of work covered topics including:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments
  • Ubiquitin and proteasome pathways
  • HER2/EGFR in Cancer Research
  • Histone Deacetylase Inhibitors Research

Among the frequent coauthors with whom Holyoake collaborated were:

  • Mhairi Copland
  • Richard E. Clark
  • Anne-Louise Latif
  • Ashley Newcombe
  • Neil Robertson

The scientist published extensively in a select group of venues, including:

  • Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Cancer Cell
  • Blood

Recent papers by Tessa L. Holyoake include:

  • A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease, 2020, Leukemia
  • BRD4-mediated repression of p53 is a target for combination therapy in AML, 2021, Nature Communications
  • CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy, 2020, Leukemia
  • BRD4-mediated repression of p53 is a target for combination therapy in AML, 2020, bioRxiv (Cold Spring Harbor Laboratory)
  • Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia, 2020, Cancer Cell

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

    Susan M. Graham;Heather G. Jørgensen;Elaine Allan;Charlie Pearson

  • Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

    Mhairi Copland;Ashley Hamilton;Lucy J. Elrick;Janet W. Baird

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

    Cristian Bellodi;Maria Rosa Lidonnici;Ashley Hamilton;G. Vignir Helgason

  • Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

    Tessa Holyoake;Xiaoyan Jiang;Connie Eaves;Allen Eaves

  • Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

    Ashley Hamilton;G. Vignir Helgason;Mirle Schemionek;Bin Zhang

  • Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib

    Ling Li;Lisheng Wang;Liang Li;Zhiqiang Wang

  • Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells

    Elodie M Kuntz;Pablo Baquero;Alison M Michie;Karen Dunn

  • Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

    Bin Zhang;Yin Wei Ho;Qin Huang;Takahiro Maeda

  • Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.

    Heather G. Jørgensen;Elaine K. Allan;Elaine K. Allan;Niove E. Jordanides;Joanne C. Mountford;Joanne C. Mountford

  • Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

    Bin Zhang;Adam C. Strauss;Su Chu;Min Li

  • Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia

    Xiaoyan Jiang;Angel Lopez;Tessa Holyoake;Allen Eaves

  • Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling

    Bin Zhang;Min Li;Tinisha McDonald;Tessa L. Holyoake

  • The chronic myeloid leukemia stem cell: stemming the tide of persistence.

    Tessa L. Holyoake;David Vetrie

  • Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow.

    Tessa L Holyoake;Franck E Nicolini;Connie J Eaves

  • Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry

    Tim H. Brümmendorf;Tessa L. Holyoake;Nathalie Rufer;Michael J. Barnett

  • PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

    Paolo Neviani;Jason G. Harb;Joshua J. Oaks;Ramasamy Santhanam

  • Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin–null mice

    H. Glimm;W. Eisterer;K. Lee;J. Cashman

  • Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells (vol 119, pg 1109, 2009)

    C Bellodi;Lidonnici;A Hamilton;GV Helgason

Frequent Co-Authors

Ravi Bhatia
Ravi Bhatia University of Alabama at Birmingham
Connie J. Eaves
Connie J. Eaves University of British Columbia
Xiaoyan Jiang
Xiaoyan Jiang University of British Columbia
Bruno Calabretta
Bruno Calabretta Thomas Jefferson University
Anthony D. Whetton
Anthony D. Whetton University of Manchester
Tim H. Brümmendorf
Tim H. Brümmendorf RWTH Aachen University
Allen C. Eaves
Allen C. Eaves Stemcell Technologies
John M. Goldman
John M. Goldman Imperial College London
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Jane F. Apperley
Jane F. Apperley Imperial College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine but want flexible options, there are a variety of related online degrees and alternative career paths to explore. Many students start their journey in healthcare by pursuing nursing. For those looking to bypass entrance exams, there are nursing schools that don't require teas or hesi, making it easier to get started.

Another popular choice is healthcare management. Earning an online degree from one of the healthcare administration degree programs can open doors to leadership roles in hospitals, clinics, and health organizations.

For nurses seeking advanced practice roles, there are asn to nurse practitioner programs available online. These bridge programs allow registered nurses to accelerate their education and expand their scope of practice.

Nutrition is another growing field within healthcare. Consider pursuing an online degree from one of the best online food science degree programs to enter careers in wellness, public health, or the food industry.

Each of these educational paths offers unique opportunities and flexible study options for aspiring healthcare professionals.

Best Scientists Citing Tessa L. Holyoake

Recently Published Articles